- Home
- ACRV vs LTRN Comparison
ACRV vs LTRN Comparison
Compare ACRV & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- LTRN
- Stock Information
- Founded
- ACRV 2018
- LTRN 2013
- Country
- ACRV United States
- LTRN United States
- Employees
- ACRV N/A
- LTRN N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- LTRN Health Care
- Exchange
- ACRV Nasdaq
- LTRN Nasdaq
- Market Cap
- ACRV 40.4M
- LTRN 36.0M
- IPO Year
- ACRV 2022
- LTRN 2020
- Fundamental
- Price
- ACRV $1.26
- LTRN $4.77
- Analyst Decision
- ACRV Buy
- LTRN Strong Buy
- Analyst Count
- ACRV 7
- LTRN 1
- Target Price
- ACRV $17.60
- LTRN $25.00
- AVG Volume (30 Days)
- ACRV 287.7K
- LTRN 591.8K
- Earning Date
- ACRV 08-12-2025
- LTRN 08-11-2025
- Dividend Yield
- ACRV N/A
- LTRN N/A
- EPS Growth
- ACRV N/A
- LTRN N/A
- EPS
- ACRV N/A
- LTRN N/A
- Revenue
- ACRV N/A
- LTRN N/A
- Revenue This Year
- ACRV N/A
- LTRN N/A
- Revenue Next Year
- ACRV $1,037.93
- LTRN N/A
- P/E Ratio
- ACRV N/A
- LTRN N/A
- Revenue Growth
- ACRV N/A
- LTRN N/A
- 52 Week Low
- ACRV $1.05
- LTRN $2.55
- 52 Week High
- ACRV $10.16
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- ACRV 43.05
- LTRN 68.37
- Support Level
- ACRV $1.34
- LTRN $3.83
- Resistance Level
- ACRV $1.48
- LTRN $4.43
- Average True Range (ATR)
- ACRV 0.10
- LTRN 0.47
- MACD
- ACRV -0.01
- LTRN 0.05
- Stochastic Oscillator
- ACRV 17.24
- LTRN 90.41
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.